


Op/1614



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Mel Epstein and Kjesten A. Wiig

Application No.: 10/003,740 Group: 1614

Filed: October 31, 2001 Examiner: Kwon, B. Y. S.

Confirmation No.: 2709

For: METHODS AND COMPOSITIONS FOR REGULATING MEMORY  
CONSOLIDATION

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
<u>1/13/04</u> Date	<u>Carol M. Bowerman</u> Signature
<u>Carol M. Bowerman</u> Typed or printed name of person signing certificate	

TRANSMITTAL OF INTERNATIONAL SEARCH REPORT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Enclosed herewith is a copy of the International Search Report (ISR) prepared by the International Searching Authority under the Patent Cooperation (PCT) Treaty in a related PCT application. The ISR identifies the same references identified in the Invitation to Pay Additional Fees, in the related PCT application, a copy of which was filed with the United States Patent and Trademark Office on September 5, 2003.

Although Applicants believe no fees are due in this matter, please charge any deficiencies in fees to Deposit Account No. 08-0380. One additional copy of this document is enclosed for accounting purposes.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Mary K. Murray  
Mary K. Murray  
Registration No. 47,813  
Telephone: (978) 341-0036  
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Date:

January 13, 2004

## PATENT COOPERATION TREATY

DOCKETED  
CEZ

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

To:  
HAMILTON, BROOK, SMITH &  
REYNOLDS, P.C.  
Attn. David E. Brook  
530 Virginia Road  
P.O. Box 9133  
Concord, MA 01742-9133  
UNITED STATES OF AMERICA

## INVITATION TO PAY ADDITIONAL FEES

(PCT Article 17(3)(a) and Rule 40.1)

25 SE 2003 SRU

Date of mailing (day/month/year)	26/08/2003
Applicant's or agent's file reference NIIN-PWO-011 3474.1001-004	PAYMENT DUE within 45 <del>xxx</del> days/days from the above date of mailing
International application No. PCT/US 01/45793	International filing date (day/month/year) 31/10/2001
Applicant SENTION, INC	

## 1. This International Searching Authority

- (i) considers that there are 05 (number of) inventions claimed in the international application covered by the claims indicated ~~xxx~~ on the extra sheet:

and it considers that the international application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated ~~xxx~~ on the extra sheet:

- (ii) ☒ has carried out a partial international search (see Annex) ☐ will establish the international search report on those parts of the international application which relate to the invention first mentioned in claims Nos.:  
see annex

- (iii) will establish the international search report on the other parts of the international application only if, and to the extent to which, additional fees are paid


## 2. The applicant is hereby invited, within the time limit indicated above, to pay the amount indicated below:

EUR 945,00 x 04 = EUR 3.780,00  
Fee per additional invention number of additional inventions total amount of additional fees

Or, \_\_\_\_\_ x \_\_\_\_\_ = \_\_\_\_\_

The applicant is informed that, according to Rule 40.2(c), the payment of any additional fee may be made under protest, i.e., a reasoned statement to the effect that the international application complies with the requirement of unity of invention or that the amount of the required additional fee is excessive.

3. ☒ Claim(s) Nos. see annex have been found to be unsearchable under Article 17(2)(b) because of defects under Article 17(2)(a) and therefore have not been included with any invention.

Name and mailing address of the International Searching Authority  European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Sylvia Hermier
--	--------------------------------------

Form PCT/ISA/206 (July 1992)

RECEIVED  
SEP - 2 2003  
Rec'd IFD  
HAMILTON, BROOK,  
SMITH & REYNOLDS, P.C.

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-49 (partially), 50 (entirely), 51-52 (partially), 53-54 (entirely), 55-75 (partially), 76 (entirely), 77-78 (partially), 79 (entirely), 88-90 (entirely)

A use and pharmaceutical kit or preparation for enhancing memory or for treating or preventing amnesia or learning disabilities or for treating or preventing memory impairment in an animal susceptible to or suffering from a psychiatric disorder, selected from anxiety, depression or schizophrenia.

2. Claims: 1-49 (partially), 51-52 (partially), 55-75 (partially), 77-78 (partially)

A use and pharmaceutical kit or preparation comprising one or more amphetamine compound(s) for treating or preventing memory impairment in an animal susceptible to or suffering from age-associated memory impairment, minimal cognitive impairment, dementia, memory impairment associated with toxicant exposure, brain injury, brain aneurysm, Parkinson's disease, head trauma, Huntington's disease, Creutzfeldt-Jacob disease, stroke, epilepsy, mental retardation, Alzheimer's disease, age or AIDS-related dementia.

3. Claims: 1-49 (partially), 51-52 (partially), 55-75 (partially), 77-78 (partially)

A use and pharmaceutical kit or preparation comprising one or more amphetamine compound(s) for treating or preventing memory impairment in an animal susceptible to or suffering from Pick's disease.

4. Claims: 1-49 (partially), 51-52 (partially), 55-75 (partially), 77-78 (partially)

A use and pharmaceutical kit or preparation comprising one or more amphetamine compound(s) for treating or preventing memory impairment in an animal susceptible to or suffering from attention deficit disorder or attention deficit hyperactivity disorder.

5. Claims: 24-47 (partially)

Use of an amphetamine compound in the manufacture of a medicament for prophylaxis or treatment of an animal susceptible to or suffering from anxiety, depression,

minimal cognitive impairment, dementia, brain injury, brain aneurysm, Parkinson's disease, head trauma, Huntington's disease, Pick's disease, Creutzfeldt-Jacob disease, stroke, schizophrenia, epilepsy, mental retardation, Alzheimer's disease, age, attention deficit disorder, attention deficit hyperactivity disorder or AIDS-related dementia, as far as diminished memory is not a symptom.

The first problem underlying the present application is to provide an alternative means for enhancing (long-term) memory and for treating or preventing amnesia or learning disabilities and for treating or preventing memory impairment. The proposed solution is the use of an amphetamine compound.

The second problem underlying the present application is to provide an alternative means for the prophylaxis or treatment of an animal susceptible to or suffering from anxiety, depression, minimal cognitive impairment, dementia, brain injury, brain aneurysm, Parkinson's disease, head trauma, Huntington's disease, Pick's disease, Creutzfeldt-Jacob disease, stroke, schizophrenia, epilepsy, mental retardation, Alzheimer's disease, age, attention deficit disorder, attention deficit hyperactivity disorder or AIDS-related dementia, as far as diminished memory is not a symptom. The proposed solution is the use of an amphetamine compound.

Thus, in the context of the alleged invention, the use of an amphetamine in for the treatment of behavioral or neurological diseases or Pick's disease (having memory impairment as a symptom or not) is the alleged contribution over the prior art and the special technical feature which may, a priori, unify the plurality of different inventions.

The idea to use amphetamines for the treatment of behavioral or neurological diseases or Pick's disease has been previously disclosed. See for example US4034113, which discloses the use of amphetamine derivatives for the treatment of geriatric patients suffering from chronic organic brain disease and Parkinsonism (column 1, line 65 - column 3, line 2; column 3, lines 42-58; column 5, lines 13-18; column 5, line 57 - column 6, lines 26).

Therefore, the idea to use amphetamines in the treatment of behavioral or neurological diseases or Pick's disease is not novel and cannot be considered as the special technical feature which may unify the plurality of different inventions. No further technical feature(s) can be identified which may be regarded as a "special technical feature" involved in the technical relationship between the different (groups of) inventions. Therefore, two groups of inventions have been defined, relating to the first and second problem, respectively, as defined above.

With respect to the first group of inventions (first problem), the use of an amphetamine for enhancing (long-term) memory and for treating or preventing memory impairment is the alleged contribution over the prior art and the special technical feature which may, a priori, unify the plurality of different inventions, in particular the

treatment of memory impairment in the specific patients claimed.

However, the idea to use amphetamines for enhancing (long-term) memory and for treating or preventing memory impairment is already known from the prior art. For example, Soetens et al. disclose in *Psychopharmacology*, 119(2), 155-162, 1995 that d-amphetamine enhances long-term retention in humans, leaving the short-term memory unaffected (abstract; p. 156, right-hand column, par. 1; p. 160, right-hand column, par. 2 - p. 161, left-hand column, par. 1). Reus et al. state in *Biological Psychiatry*, 14(2), 345-356, 1979 that intravenous d-amphetamine improves memory and memory consolidation in depressed patients (abstract; p. 346, par. 3-4; p. 348, par. 4; p. 353, par. 2 - p. 354, par. 2).

Therefore, the idea to use amphetamines for enhancing (long-term) memory and for treating or preventing memory impairment is not novel and cannot be considered as the special technical feature which may unify the plurality of different inventions. No further technical feature(s) can be identified which may be regarded as a "special technical feature" involved in the technical relationship between the different (groups of) inventions.

Consequently, the present application lacks unity of invention and the different solutions not belonging to a common inventive concept are detailed as the different subjects listed above.

The first group of inventions, relating to the first problem, has been further subdivided based on the specific patient. Each of the inventions listed is a distinct invention, characterised by its own special technical feature, defining the contribution which each of the claimed inventions makes over the prior art.

As searching the further inventions would have caused a major additional searching effort, only the first invention was searched.

The application relates to a plurality of inventions, or groups of inventions, in the sense of Rule 13.1 PCT. They have been divided as defined above. If the applicant pays additional fees for one (or more) not yet searched group(s) of invention(s), then the further search(es) may reveal further prior art that gives evidence of a further lack of unity 'a posteriori' within one (or more) of the not yet searched group(s). In such a case only the first invention in this (each of these) group(s) of inventions, which is considered to lack unity of invention, will be the subject of a search.

No further invitation to pay further additional fees will be issued. This is because Article 17(3)(a) PCT stipulates that the ISA shall establish the International Search Report on those parts of the international application which relate to the invention first mentioned in the claims ('main invention') and for those parts which relate to inventions in respect of which the additional fees were paid. Neither the PCT nor the PCT guidelines provide a legal basis for further invitations to pay further additional search fees (W17/00, point 11 and W1/97, points 11-16).

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 206

Continuation of Box 3.

Although claims 55-78 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----  
Further defect(s) under Article 17(2)(a):

Continuation of Box 3.

Claims Nos.: 80-87

Present claims 4, 7-12, 14-17, 22, 24, 27-50, 55-78, 88-90 relate to compounds which are actually not well-defined. The use of the definitions "a metabolite or prodrug" (claims 4, 7-12, 24, 27-50, 56, 59-78, 88-90), "eutomer or distomer" (claims 14-17, 37-40, 55-78), "a neuronal growth factor", "a neuronal survival factor", "a neuronal trophic factor", "a cholinergic modulator", "an adrenergic modulator", "a nonadrenergic modulator", "a dopaminergic modulator", "a glutaminergic modulator", "an agent that stimulates the PKC, PKA, GABA, NMDA, cannabinoid, AMPA, kainate, PDE, CREB or nootropic pathways" (claims 22, 45, 71) in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. The lack of clarity is such as to render a meaningful complete search impossible.

In addition, claims 1-7, 12-27, 32-50, 55-59, 79 and 88-90 relate to a very large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Moreover, claims 80-87 relate to a method of doing business, which the International Searching Authority is not required, under the regulations, to search (Article 17(2)(a)(i) PCT and Rule 39(iii) PCT).

Consequently, the search for the first invention has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds specified in claims 8-11, 28-31, 51-54 and 60-63, optionally in combination with methylphenidate or the adrenergic modulators dopamine, norepinephrine or epinephrine (description p. 30, lines 21-31), and their use in enhancing long-term memory and in the treatment or prevention of amnesia or learning disabilities and in the treatment of memory impairment resulting from anxiety, depression and schizophrenia.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 206

the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



**Annex to Form PCT/ISA/206  
COMMUNICATION RELATING TO THE RESULTS  
OF THE PARTIAL INTERNATIONAL SEARCH**

International Application No  
PCT/US 01/45793

1. The present communication is an Annex to the invitation to pay additional fees (Form PCT/ISA/206). It shows the results of the international search established on the parts of the international application which relate to the invention first mentioned in claims Nos.:
2. This communication is not the international search report which will be established according to Article 18 and Rule 43. see 'Invitation to pay additional fees.'
3. If the applicant does not pay any additional search fees, the information appearing in this communication will be considered as the result of the international search and will be included as such in the international search report.
4. If the applicant pays additional fees, the international search report will contain both the information appearing in this communication and the results of the international search on other parts of the international application for which such fees will have been paid.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	YASAR S ET AL: "Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research." JOURNAL OF NEURAL TRANSMISSION SUPPLEMENT, vol. 48, 1996, pages 61-73, XP008020416 ISSN: 0303-6995  abstract page 61, paragraph 1 page 68, paragraph 2 -page 70, paragraph 2 page 71, paragraph 2  ---	1,4-12, 14-20, 24-33, 37-43, 48-52, 55-69, 74-79
X	GELOWITZ DOUGLAS L ET AL: "Chronic L-deprenyl or L-amphetamine: Equal cognitive enhancement, unequal MAO inhibition." PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 47, no. 1, 1994, pages 41-45, XP008020420 ISSN: 0091-3057  abstract page 41, column 1, paragraph 1 -page 42, column 1, paragraph 1 page 43, column 1, paragraph 4 -page 44, column 2, paragraph 1  ---  -/--	1,4-10, 12, 14-20, 24-30, 32,33, 37-43, 48-52, 55-62, 64-69, 76-78



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*8\* document member of the same patent family

**Annex to Form PCT/ISA/206  
COMMUNICATION RELATING TO THE RESULTS  
OF THE PARTIAL INTERNATIONAL SEARCH**

International Application No  
**PCT/US 01/45793**

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SOETENS E ET AL: "Effect of amphetamine on long-term retention of verbal material." PSYCHOPHARMACOLOGY, vol. 119, no. 2, 1995, pages 155-162, XP008020419 ISSN: 0033-3158</p> <p>abstract page 156, column 1, paragraph 2 page 156, column 2, paragraph 1 page 160, column 2, paragraph 2 -page 161, column 1, paragraph 1</p> <p align="center">---</p>	<p>1,2, 4-10,12, 14-20, 47-50, 55-62, 64-69, 73, 76-78, 88-90</p>
X	<p>GOLD P E ET AL: "MODULATION OF LONG-TERM POTENTIATION BY PERIPHERALLY ADMINISTERED AMPHETAMINE AND EPINEPHRINE" BRAIN RESEARCH, vol. 305, no. 1, 1984, pages 103-108, XP008020417 ISSN: 0006-8993</p> <p>abstract page 103, column 2, paragraph 1 page 104, column 2, paragraph 1 page 105, column 2, paragraph 2 page 106, column 2, paragraph 2</p> <p align="center">---</p>	<p>1,4-10, 14-21, 24-30, 32,33, 37-44, 48-50, 55-62, 64-70, 74-78</p>
X	<p>REUS V I ET AL: "DEXTRO AMPHETAMINE EFFECTS ON MEMORY IN A DEPRESSED POPULATION" BIOLOGICAL PSYCHIATRY, vol. 14, no. 2, 1979, pages 345-356, XP008020409 EN ISSN: 0006-3223</p> <p>abstract page 346, paragraph 3 - paragraph 4 page 348, paragraph 4 page 353, paragraph 2 -page 354, paragraph 2</p> <p align="center">---</p> <p align="center">-/--</p>	<p>1,4-10, 12, 14-20, 24-30, 32,33, 37-43, 48,49, 55-62, 64-69, 74,75, 77,78</p>

Annex to Form PCT/ISA/206  
COMMUNICATION RELATING TO THE RESULTS  
OF THE PARTIAL INTERNATIONAL SEARCH

International Application No  
PCT/US 01/45793

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KIRrane RICHELLE M ET AL: "Effects of amphetamine on visuospatial working memory performance in schizophrenia spectrum personality disorder." NEUROPSYCHOPHARMACOLOGY, vol. 22, no. 1, January 2000 (2000-01), pages 14-18, XP001162739 ISSN: 0893-133X abstract page 15, column 2, paragraph 3 -page 16, column 1, paragraph 3 page 17, column 1, paragraph 2 - paragraph 3	1,2, 4-10, 18-20, 24-30, 32-34, 48,49,79
X	BARCh D M ET AL: "The effects of D-amphetamine on language function in schizophrenia." SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 23, no. 1-2, 1997, page 1952 XP001157878 27th Annual Meeting of the Society for Neuroscience;New Orleans, Louisiana, USA; October 25-30, 1997 ISSN: 0190-5295  the whole document	1,4-10, 12, 14-20, 24-30, 32,33, 37-40, 48,49, 55-62, 64-66, 74,75, 77-79
X	QUARTErMAIN D ET AL: "AMPHETAMINE ENHANCES RETRIEVAL FOLLOWING DIVERSE SOURCES OF FORGETTING" PHYSIOLOGY & BEHAVIOR, vol. 43, no. 2, 1988, pages 239-242, XP008020418 ISSN: 0031-9384  abstract page 239, column 1, paragraph 2 page 241, column 1, paragraph 2 -column 2, paragraph 2  -/--	1,4-10, 12-21, 24-30, 32,33, 37-40, 44,48, 49, 55-62, 64-66, 70,74, 75,77-79

**Annex to Form PCT/ISA/206  
COMMUNICATION RELATING TO THE RESULTS  
OF THE PARTIAL INTERNATIONAL SEARCH**

International Application No  
PCT/US 01/45793

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>QUARTERMAIN D ET AL: "ALLEVIATION OF SCOPOLAMINE AMNESIA BY RETRIEVAL ENHANCING TREATMENTS". PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 30, no. 4, 1988, pages 1093-1096, XP008020412 ISSN: 0091-3057</p> <p>abstract page 1093, column 1 page 1095, column 1, paragraph 5 -column 2, paragraph 3</p>	<p>1,4-10, 12, 14-20, 24-30, 32,33, 37-40, 48,49, 55-62, 64-66, 74,75, 77-79</p>
X	<p>US 5 422 355 A (WHITE JOHN F ET AL) 6 June 1995 (1995-06-06)</p> <p>column 3, line 51 -column 5, line 36 column 10, line 27 - line 34 column 11, line 21 - line 40 claims 1,7</p>	<p>1,2,4-6, 18-21, 24-26, 32-34, 44, 48-50, 76-79, 88-90</p>
X	<p>WO 99 16746 A (HOECHST MARION ROUSSEL INC) 8 April 1999 (1999-04-08)</p> <p>page 1, paragraph 1 -page 4, paragraph 9 page 9, paragraph 3 page 18, paragraph 4 page 23, paragraph 11 -page 24, paragraph 1 page 28, paragraph 2 -page 29, paragraph 2 claims 1,3,5,114,115,170,171</p> <p align="center">-/--</p>	<p>1,2,4-7, 12, 18-21, 24-27, 32-34, 44, 48-50, 76,79, 88-90</p>

**Annex to Form PCT/ISA/206  
COMMUNICATION RELATING TO THE RESULTS  
OF THE PARTIAL INTERNATIONAL SEARCH**

International Application No  
**PCT/US 01/45793**

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 97 17067 A (DISANTO ANTHONY R ; SOMERSET PHARMACEUTICALS INC (US)) 15 May 1997 (1997-05-15)</p> <p>page 1, line 10 - line 16 page 5, line 17 - line 32 page 6, line 22 - page 7, line 7 page 7, line 27 - page 8, line 2 examples 1-3</p>	<p>1, 2, 4-6, 12, 14-21, 24-26, 32-34, 37-40, 44, 47-50, 55-58, 64-66, 70, 74-79, 88-90</p>
X	<p>WO 00 32556 A (SEPRACOR INC) 8 June 2000 (2000-06-08)</p> <p>page 3, line 1 - line 32 page 4, line 34 - page 5, line 12 page 6, line 11 - line 16 page 7, line 35 - page 8, line 2 page 16, line 3 - line 12 page 17, line 14 - line 31 page 19, line 3 - line 7 examples 5.7.1-5.7.2 claims 1, 4-6, 12-15, 36, 37, 40</p>	<p>1-5, 12-20, 24, 25, 32-43, 48-50, 55-57, 64-69, 73-79, 88, 89</p>
X	<p>PARKES J D ET AL: "Amphetamines in the treatment of Parkinson's disease." JOURNAL OF NEUROLOGY, NEUROSURGERY, AND PSYCHIATRY. ENGLAND MAR 1975, vol. 38, no. 3, March 1975 (1975-03), pages 232-237, XP008020423 ISSN: 0022-3050 abstract page 233, column 1, paragraph 2 - paragraph 3</p>	<p>1, 2, 4-10, 12, 14-20, 22, 48, 49, 51, 53, 54, 79, 88-90</p>
X	<p>FR 2 108 032 A (CONTROLLED MEDICATIONS) 12 May 1972 (1972-05-12)</p> <p>example 3</p>	<p>1, 2, 4-10, 12, 14-21, 48, 49, 79, 88-90</p>

**Annex to Form PCT/ISA/206  
COMMUNICATION RELATING TO THE RESULTS  
OF THE PARTIAL INTERNATIONAL SEARCH**

International Application No  
PCT/US 01/45793

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 00 59479 A (CHUNGI SHUBHA ;MIDHA KAMAL K (US); PHARMAQUEST LTD (US); IORIO THE) 12 October 2000 (2000-10-12)</p> <p>page 3, line 22 - line 26 page 4, line 15 - line 25 page 12, line 29 -page 13, line 14 page 14, line 26 - line 28 claims 17-19</p> <p align="center">---</p>	<p>1,2, 4-10,12, 14-21, 23,48, 49,79, 88-90</p>
X	<p>WO 00 01379 A (WARNER LAMBERT CO ;RAVEN PETER (US); BOOTH ANTHONY R (US); CAFFREY) 13 January 2000 (2000-01-13)</p> <p>page 1, line 6 - line 9 page 2, line 28 -page 2, line 2 page 5, line 24 - line 30 page 6, line 10 - line 14 page 8, line 15 - line 28 page 21, line 8 - line 9 claim 1</p> <p align="center">---</p>	<p>1,2,6-9, 11, 13-21, 48,49, 79,90</p>
X	<p>WO 97 26871 A (PESTERFIELD E CHARLES JR) 31 July 1997 (1997-07-31)</p> <p>page 1, paragraph 1 page 2, paragraph 2 page 4, paragraph 2 -page 5, paragraph 1 page 5, paragraph 3 page 7, paragraph 2 claims 1,4,8,9,13,15</p> <p align="center">---</p>	<p>1-3,6,7, 12-16, 18-20, 48,49, 79,90</p>
X	<p>US 4 034 113 A (SHULGIN ALEXANDER T) 5 July 1977 (1977-07-05)</p> <p>column 1, line 65 -column 3, line 2 column 3, line 42 - line 58 column 5, line 13 - line 18 column 5, line 57 -column 6, line 25 claims</p> <p align="center">---</p> <p align="center">-/--</p>	<p>1,2,4,5, 12-20, 24,25, 32-34, 37-43, 47-50, 55,56, 64-69, 73-78, 88,89</p>

**Annex to Form PCT/ISA/206  
COMMUNICATION RELATING TO THE RESULTS  
OF THE PARTIAL INTERNATIONAL SEARCH**

International Application No  
**PCT/US 01/45793**

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	YONKOV D I: "PARTICIPATION OF CHOLINERGIC MECHANISMS IN THE MEMORY EFFECTS OF CNS STIMULANTS" ADVANCED IN THE BIOSCIENCES, PERGAMON PRESS, GB, vol. 59, 1986, pages 347-350, XP008002362 ISSN: 0065-3446	1,4-10, 18-20, 24-30, 41-43, 48-50, 55-61, 67-69, 74-79, 88-90
A	the whole document	46,72
A	--- DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1975 STEIN L ET-AL: "MEMORY ENHANCEMENT BY CENTRAL ADMINISTRATION OF NOREPINEPHRINE" Database accession no. PREV197559062381 XP002250439 abstract & BRAIN RESEARCH, vol. 84, no. 2, 1975, pages 329-335, ISSN: 0006-8993	22,45,71
A	--- NICOLAUS B J R: "Symbiotic Approach to Drug Design" DECISION MAKING IN DRUG RESEARCH, XX, XX, 1983, pages 173-186, XP002197412 the whole document	
E	--- WO 02 053104 A (EPSTEIN MEL H ;SENTION INC (US); WIIG KJESTEN A (US)) 11 July 2002 (2002-07-11) figures 4-21 page 33, line 12 -page 36, line 2 -----	1-79, 88-90

# Patent Family Annex

Information on patent family members

International Application No

PCT/US 01/45793

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5422355	A	06-06-1995	US 5260331 A AT 113833 T AU 641394 B2 AU 5608090 A CA 2017966 A1 DD 294706 A5 DE 69013994 D1 DE 69013994 T2 EP 0407032 A2 ES 2063268 T3 GB 2233558 A ,B HU 58270 A2 JP 3047155 A PT 94218 A US 5086073 A	09-11-1993 15-11-1994 23-09-1993 06-12-1990 02-12-1990 10-10-1991 15-12-1994 13-04-1995 09-01-1991 01-01-1995 16-01-1991 28-02-1992 28-02-1991 08-02-1991 04-02-1992
WO 9916746	A	08-04-1999	AU 752008 B2 AU 9305598 A BR 9812694 A CA 2302412 A1 EP 1032559 A1 JP 2001518463 T WO 9916746 A1	05-09-2002 23-04-1999 22-08-2000 08-04-1999 06-09-2000 16-10-2001 08-04-1999
WO 9717067	A	15-05-1997	AT 219358 T AU 707646 B2 AU 7608096 A CA 2236368 A1 CN 1207675 A DE 69621946 D1 DE 69621946 T2 DK 866691 T3 EP 0866691 A1 ES 2180809 T3 JP 11504944 T NO 982044 A PT 866691 T US 6117912 A WO 9717067 A1	15-07-2002 15-07-1999 29-05-1997 15-05-1997 10-02-1999 25-07-2002 30-01-2003 14-10-2002 30-09-1998 16-02-2003 11-05-1999 02-07-1998 29-11-2002 12-09-2000 15-05-1997
WO 0032556	A	08-06-2000	US 6342533 B1 AU 2474900 A CA 2352324 A1 EP 1135359 A1 US 2002086904 A1 WO 0032556 A1 US 2003018083 A1	29-01-2002 19-06-2000 08-06-2000 26-09-2001 04-07-2002 08-06-2000 23-01-2003
FR 2108032	A	12-05-1972	GB 1359643 A BE 773113 A1 CA 952431 A1 DE 2148391 A1 FR 2108032 A1 NL 7113307 A US 3728445 A	10-07-1974 17-01-1972 06-08-1974 06-04-1972 12-05-1972 30-03-1972 17-04-1973
WO 0059479	A	12-10-2000	AU 4221300 A AU 4334700 A	23-10-2000 23-10-2000



# Patent Family Annex

Information on patent family members

International Application No

PCT/US 01/45793

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0059479	A		CA 2366791 A1	12-10-2000
			CA 2368367 A1	12-10-2000
			EP 1191924 A1	03-04-2002
			EP 1165054 A1	02-01-2002
			JP 2002541092 T	03-12-2002
			JP 2002541093 T	03-12-2002
			WO 0059479 A1	12-10-2000
			WO 0059481 A1	12-10-2000
			US 6217904 B1	17-04-2001
			US 6340476 B1	22-01-2002
			US 2002058061 A1	16-05-2002
WO 0001379	A	13-01-2000	AU 4335799 A	24-01-2000
			EP 1091733 A1	18-04-2001
			WO 0001379 A1	13-01-2000
			US 6495529 B1	17-12-2002
WO 9726871	A	31-07-1997	US 5708036 A	13-01-1998
			AU 2247997 A	20-08-1997
			CA 2247953 A1	31-07-1997
			EP 0892639 A1	27-01-1999
			WO 9726871 A1	31-07-1997
US 4034113	A	05-07-1977	NONE	
WO 02053104	A	11-07-2002	WO 02053104 A2	11-07-2002
			US 2002161002 A1	31-10-2002